PAPER Harris PA, Berger SB, Jeong JU, Nagilla R, Bandyopadhyay D, Campobasso N, Capriotti CA, Cox JA, Dare L, Dong X, Eidam PM, Finger JN, Hoffman SJ, Kang J, Kasparcova V, King BW, Lehr R, Lan Y, Leister LK, Lich JD, MacDonald TT, Miller NA, Ouellette MT, Pao CS, Rahman A, Reilly MA, Rendina AR, Rivera EJ, Schaeffer MC, Sehon CA, Singhaus RR, Sun HH, Swift BA, Totoritis RD, Vossenkämper A, Ward P, Wisnoski DD, Zhang D, Marquis RW, Gough PJ, Bertin J

Discovery of a First-in-Class Receptor Interacting Protein 1 (RIP1) Kinase Specific Clinical Candidate (GSK2982772) for the Treatment of Inflammatory Diseases.

J Med Chem. 2017 Feb 23;60(4):1247-1261. Epub 2017 Feb 10 PubMed: 28151659

Apabetalone

THERAPEUTICS Resverlogix Corporation RVX208 RVX000222 Small Molecule Other The Phase 3 BETonMACE trial evaluated apabetalone in 2,425 people with Type 2 diabetes and coronary artery disease on a primary outcome of number of major cardiovascular events. The trial inclu

Ryoan Zobuk

North Port, United States

PAPER Miron VE, Boyd A, Zhao JW, Yuen TJ, Ruckh JM, Shadrach JL, van Wijngaarden P, Wagers AJ, Williams A, Franklin RJ, Ffrench-Constant C

M2 microglia and macrophages drive oligodendrocyte differentiation during CNS remyelination.

Nat Neurosci. 2013 Sep;16(9):1211-1218. Epub 2013 Jul 21 PubMed: 23872599

Susan Walczak

Ho-Chunk Nation
Wisconsin Dells, United States

PAPER Lynch SY, Kaplow J, Zhao J, Dhadda S, Luthman J, Albala B

Elenbecestat, E2609, a Bace Inhibitor: Results From a Phase-2 Study in Subjects With Mild Cognitive Impairment and Mild-to-Moderate Dementia Due to Alzheimer's Disease

Alzheimer's & Dementia, July 2018

Latozinemab

THERAPEUTICS Alector GlaxoSmithKline (GSK) AL001 GSK4527223 Immunotherapy (passive) Other In September 2018, a first-in-human trial started enrolling 64 healthy adults and people with progranulin mutations causative for FTD at eight sites across North America and the

Greg Czyryca on Keep Your Enthusiasm? Scientists Process Brutal Trial Data

COMMENT My comment will be primarily influenced by the structure of the Aβ 1-42 peptide DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA (PDB 2MXU) and its mechanistic implications. The hydrophilic N-terminus is a relatively poorly organized region where antibodies bin

Antoine Chevrette

France

PAPER Bouybayoune I, Comerio L, Pasetto L, Bertani I, Bonetto V, Chiesa R

Cyclophillin A deficiency accelerates RML-induced prion disease.

Neurobiol Dis. 2019 Oct;130:104498. Epub 2019 Jun 8 PubMed: 31181281

PAPER Cressatti M, Song W, Turk AZ, Garabed LR, Benchaya JA, Galindez C, Liberman A, Schipper HM

Glial HMOX1 expression promotes central and peripheral α-synuclein dysregulation and pathogenicity in parkinsonian mice.

Glia. 2019 Sep;67(9):1730-1744. Epub 2019 Jun 10 PubMed: 31180611

PAPER Fujiwara S, Kono F, Matsuo T, Sugimoto Y, Matsumoto T, Narita A, Shibata K

Dynamic Properties of Human α-Synuclein Related to Propensity to Amyloid Fibril Formation.

J Mol Biol. 2019 Aug 9;431(17):3229-3245. Epub 2019 Jun 8 PubMed: 31181290

PAPER Ho YJ, Shen MS, Tai CH, Li HH, Chen JH, Liao WC, Chiu PY, Lee IY, Lin CL, Hung CS

Use of Ceftriaxone in Treating Cognitive and Neuronal Deficits Associated With Dementia With Lewy Bodies.

Front Neurosci. 2019;13:507. Epub 2019 May 24 PubMed: 31178684

PAPER Carmona-Abellan M, Gabilondo I, Murueta-Goyena A, Khurana V, Tijero B, Luquin MR, Acera M, Del Pino R, Gardeazabal J, Martínez-Valbuena I, Sanchez-Pernaute R, Gómez-Esteban JC

Small fiber neuropathy and phosphorylated alpha-synuclein in the skin of E46K-SNCA mutation carriers.

Parkinsonism Relat Disord. 2019 Aug;65:139-145. Epub 2019 Jun 5 PubMed: 31178336

PAPER Kuo MT, Beckman JS, Shaw CA

Neuroprotective effect of CuATSM on neurotoxin-induced motor neuron loss in an ALS mouse model.

Neurobiol Dis. 2019 Oct;130:104495. Epub 2019 Jun 7 PubMed: 31181282